Shanghai perhum therapeutics
Webb10 nov. 2024 · May 5, 2024 updated by: Shanghai PerHum Therapeutics Co., Ltd. A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT301-38) in Patients With Relapsed or Refractory AXL Positive Sarcomas. Webb12 sep. 2024 · There are two main strategies to develop drugs targeting Axl-GAS6. One is to directly inhibit Axl, and the other is to inhibit GAS6 to prevent its binding to Axl, i.e., ligand capture. These drugs are suitable for tumor drug resistance therapy or …
Shanghai perhum therapeutics
Did you know?
Webb22 maj 2024 · Shanghai PerHum Therapeutics Co., Ltd. Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record Study Description Go to Brief … Webb8 maj 2024 · Arms, Groups and Cohorts. Experimental: CCT301-59. The safety and preliminary therapeutic efficacy of CCT301-59 will be evaluated for subjects with ROR2 positive biopsy in a standard 3+3 dose escalation rule. Three dose levels of CAR T will be administered in this study: 1×10^6, 3×10^6, 1×10^7 CCT301-59 CAR positive T cells/kg …
Webb22 feb. 2024 · Contact Information Website www.perhum.com Formerly Known As Shanghai Weiming Xuhang Biotechnology Co., Ltd., Shanghai Xuhang Biotechnology Co., Ltd. Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Biotechnology Other Industries Laboratory Services (Healthcare) … Webb10 aug. 2024 · Shanghai PerHum Therapeutics Co., Ltd. Collaborator Shanghai Zhongshan Hospital Provider of Information About this Clinical Study Sponsor Conditions in This Trial Solid Tumor Gastric Cancer Breast Cancer Ovarian Cancer Sarcoma Additional Key Areas Provided by Investigators HER2 CAR-T Solid tumors Interventions in This Trial CCT303-406
Webb21 maj 2024 · EXUMA Biotechnology’s Affiliate Shanghai PerHum Therapeutics Announces Preliminary Results of Two First-in-Human Solid Tumor CAR-T Products Data … Webb13 nov. 2024 · SHANGHAI and WEST PALM BEACH, Fla., November 13, 2024 — F1 Oncology, Inc., a biotechnology company discovering and developing adoptive cellular therapies (ACTs) for solid tumors, today announced that its international affiliate, EXUMA Biotechnology Hong Kong, has formed Shanghai EXUMA Biotechnology Co., Ltd., a …
Webb21 maj 2024 · MAINZ, Germany--(BUSINESS WIRE)-- EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics announced today interim results of two first-in-human …
http://asiatoday.com/pressrelease/exuma-biotechnology%E2%80%99s-affiliate-shanghai-perhum-therapeutics-announces-preliminary-resu hilite realtyWebb21 maj 2024 · EXUMA Biotechnology’s Affiliate Shanghai PerHum Therapeutics Announces Preliminary Results of Two First-in-Human Solid Tumor May 21, 2024, 9:00 … hilite projects pvt ltdWebbA Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (clinicaltrials.gov) - P1 N=15 Recruiting Sponsor: Shanghai PerHum Therapeutics Co., Ltd. Trial completion date: Apr 2024 --> Oct 2024 Trial primary completion date: Apr 2024 --> Oct 2024. hilite photographyWebb15 feb. 2024 · • The leading HER2-Positive Breast Cancer Companies includes Ambrx, Alteogen, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus... smart ac1 ราคาWebbPerhum therapeutics has developed a modified chimeric antigen receptor ... Shanghai Pu'er Biotechnology Overview. Founded Year 2016. Location Shanghai, China. Company Stage Funding Raised. Similar Cos. Ginkgo Bioworks, Human Longevity, Amyris, Bionano Genomics, Relay Therapeutics & 3271 others. smart ac2600smart academy balernaWebb2 Shanghai PerHum Therapeutics Co. Ltd., Shanghai 200052, P.R. China. PMID: 32323752 DOI: 10.3892/ijmm.2024.4527 Abstract The expression of anillin mRNA and protein is regulated in a cell cycle‑dependent manner. However, the mechanism underlying ... hilite spelling